[
  {
    "ts": null,
    "headline": "Revvity Q2 Preview: Can Strong Segments Deliver an Earnings Beat?",
    "summary": "RVTY is likely to see another earnings beat as Diagnostics momentum and Signals Software growth offset tariff headwinds.",
    "url": "https://finnhub.io/api/news?id=e6c16a884fc7a42e09b4113e64e5872c8c6b955d4e4e0abb5e30497b57aaf54e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753369860,
      "headline": "Revvity Q2 Preview: Can Strong Segments Deliver an Earnings Beat?",
      "id": 136085403,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "CAH",
      "source": "Yahoo",
      "summary": "RVTY is likely to see another earnings beat as Diagnostics momentum and Signals Software growth offset tariff headwinds.",
      "url": "https://finnhub.io/api/news?id=e6c16a884fc7a42e09b4113e64e5872c8c6b955d4e4e0abb5e30497b57aaf54e"
    }
  },
  {
    "ts": null,
    "headline": "WST Stock Rises on Q2 Earnings Beat, EPS View Up on Tariff & FX Benefit",
    "summary": "West Pharmaceutical's second-quarter top line continues to benefit from revenue growth in its Proprietary Products segment.",
    "url": "https://finnhub.io/api/news?id=3309af54b41f307d645993810740c9168ae99fee264e066f9ab175ddb8b1e1ff",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753368360,
      "headline": "WST Stock Rises on Q2 Earnings Beat, EPS View Up on Tariff & FX Benefit",
      "id": 136085404,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "CAH",
      "source": "Yahoo",
      "summary": "West Pharmaceutical's second-quarter top line continues to benefit from revenue growth in its Proprietary Products segment.",
      "url": "https://finnhub.io/api/news?id=3309af54b41f307d645993810740c9168ae99fee264e066f9ab175ddb8b1e1ff"
    }
  },
  {
    "ts": null,
    "headline": "Will DXCM Q2 Earnings Reflect U.S. Coverage Expansion & Stelo Impact?",
    "summary": "DexCom Q2 results are likely to reflect strong growth on the back of coverage by two large PBMs and Stelo traction, driving momentum and market expansion in 2025.",
    "url": "https://finnhub.io/api/news?id=9e6b7abd610a750d98c5e72c14721a554ae2c6e6d61bc243e9030769f6599916",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753366500,
      "headline": "Will DXCM Q2 Earnings Reflect U.S. Coverage Expansion & Stelo Impact?",
      "id": 136085405,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "CAH",
      "source": "Yahoo",
      "summary": "DexCom Q2 results are likely to reflect strong growth on the back of coverage by two large PBMs and Stelo traction, driving momentum and market expansion in 2025.",
      "url": "https://finnhub.io/api/news?id=9e6b7abd610a750d98c5e72c14721a554ae2c6e6d61bc243e9030769f6599916"
    }
  },
  {
    "ts": null,
    "headline": "Can Robust Invisalign Momentum Drive Align Technology's Q2 Earnings?",
    "summary": "ALGN is likely to have delivered robust Q2 2025 performance as Invisalign traction and iTero upgrades gained steam across global markets.",
    "url": "https://finnhub.io/api/news?id=c913f1f8e73dd53bc7c4a5916e89aa38267272a8abc06dda0ca85d1676c55f62",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753366080,
      "headline": "Can Robust Invisalign Momentum Drive Align Technology's Q2 Earnings?",
      "id": 136085256,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "CAH",
      "source": "Yahoo",
      "summary": "ALGN is likely to have delivered robust Q2 2025 performance as Invisalign traction and iTero upgrades gained steam across global markets.",
      "url": "https://finnhub.io/api/news?id=c913f1f8e73dd53bc7c4a5916e89aa38267272a8abc06dda0ca85d1676c55f62"
    }
  },
  {
    "ts": null,
    "headline": "West Pharmaceutical Services (WST) Surpasses Q2 Earnings and Revenue Estimates",
    "summary": "West Pharmaceutical (WST) delivered earnings and revenue surprises of +21.85% and +5.39%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?",
    "url": "https://finnhub.io/api/news?id=6364ccf762df2dc52ab794e2c21828f4e699c204baa18a66a1932d5ff0c9da3a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753355402,
      "headline": "West Pharmaceutical Services (WST) Surpasses Q2 Earnings and Revenue Estimates",
      "id": 136066722,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "CAH",
      "source": "Yahoo",
      "summary": "West Pharmaceutical (WST) delivered earnings and revenue surprises of +21.85% and +5.39%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?",
      "url": "https://finnhub.io/api/news?id=6364ccf762df2dc52ab794e2c21828f4e699c204baa18a66a1932d5ff0c9da3a"
    }
  },
  {
    "ts": null,
    "headline": "Should You Invest in the Invesco S&P 500 Equal Weight Health Care ETF (RSPH)?",
    "summary": "Sector ETF report for RSPH",
    "url": "https://finnhub.io/api/news?id=8175dd0fee6a583d843554479c57608a8a97f58c31c61c1c134ce7928d4eb258",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753352405,
      "headline": "Should You Invest in the Invesco S&P 500 Equal Weight Health Care ETF (RSPH)?",
      "id": 136066723,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "CAH",
      "source": "Yahoo",
      "summary": "Sector ETF report for RSPH",
      "url": "https://finnhub.io/api/news?id=8175dd0fee6a583d843554479c57608a8a97f58c31c61c1c134ce7928d4eb258"
    }
  }
]